Clinical Trials Logo
  1. Home
  2. Drug-Induced Liver Injury
  3. NCT05060289

A Prognostic Model for Drug-induced Liver Injury in China — DILI-PM  

Drug-induced Liver Injury Clinical Trial

Official title:
A Prognostic Model for Drug-induced Liver Injury in China : A Multi-center, Prospective Cohort Study

Clinical Trial Summary

A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and screen novel serum markers. A prognostic model incorporating with the novel serum marker(s) for DILI would be established and validated to imporve the prognosis of patients in China .

Clinical Trial Description

Research Objectives: 1. To establish a standardized multi-center, prospective DILI cohort nationwide and obtain long-term prognostic data. 2. To establish and verify prognostic model(s) of DILI in China. 3. To explore novel serum biomarkers for the prognosis of DILI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05060289
Study type Observational [Patient Registry]
Source Beijing Friendship Hospital
Contact Yan Wang
Phone 18810530724
Email wangyanpku@163.com
Status Recruiting
Phase
Start date May 25, 2022
Completion date December 31, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Not yet recruiting NCT02061826 - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA) N/A
Completed NCT02182167 - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Phase 2/Phase 3
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Not yet recruiting NCT03091556 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill. N/A
Not yet recruiting NCT03091218 - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule. N/A
Not yet recruiting NCT03091244 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule. N/A
Not yet recruiting NCT03060252 - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill N/A
Not yet recruiting NCT03091608 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule N/A
Completed NCT02407964 - A Retrospective Study on Drug Induced Liver Injury in China N/A
Active, not recruiting NCT05144217 - Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo Phase 2/Phase 3
Completed NCT01705041 - Preliminary Evaluation of a Point-Of-Care Liver Function Test N/A
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Recruiting NCT05465642 - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed NCT01434173 - Risk of Acute Liver Injury in Users of Antimicrobials N/A
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence
Completed NCT03602703 - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3